Tapeworm drug on a dendrimer carrier slows endometriosis lesions in mice
Researchers at Washington State University and the University of Michigan slowed endometriosis lesion spread in mice with a repackaged tapeworm drug. The treatment also reduced inflammation, and the team is working toward clinical trials for a disease with limited treatment options.
The Scientist · Science desk
Hayashi's group found lesion immune cells with a folate receptor. Sharma tied niclosamide to a folate-tagged dendrimer. Hormonal drugs can bring nausea and mood swings; lesions often regrow after surgery. Mice do not naturally develop endometriosis. The team works toward clinical trials.
- capability Kanako Hayashi's group, WSU Earlier mouse work found lesion-specific immune cells that drive inflammation and growth and carry a folate receptor, claim 8
- capability Anjali Sharma, U. of Michigan Attached niclosamide to a dendrimer by click chemistry, plus a folate group to target cells with the receptor, claim 7
- cost Hormonal medications Can stall the menstrual cycle to limit lesions, but can bring nausea and mood swings, claim 14
- constraint Surgery Can remove lesions, but they often regrow, claim 14
- constraint Mouse model Mice do not naturally menstruate or develop endometriosis, so significant work remains before human replication, claim 13
- decision Research team Already working on bringing the new drug to clinical trials, claim 2
| Who | How | Kind | Claim |
|---|---|---|---|
| Kanako Hayashi's group, WSU | Earlier mouse work found lesion-specific immune cells that drive inflammation and growth and carry a folate receptor | capability | 8 |
| Anjali Sharma, U. of Michigan | Attached niclosamide to a dendrimer by click chemistry, plus a folate group to target cells with the receptor | capability | 7 |
| Hormonal medications | Can stall the menstrual cycle to limit lesions, but can bring nausea and mood swings | cost | 14 |
| Surgery | Can remove lesions, but they often regrow | constraint | 14 |
| Mouse model | Mice do not naturally menstruate or develop endometriosis, so significant work remains before human replication | constraint | 13 |
| Research team | Already working on bringing the new drug to clinical trials | decision | 2 |
What happened
- Earlier mouse work from Kanako Hayashi's group found immune cells specific to lesion tissue that drove inflammation and lesion growth and carry a folate receptor.
- Anjali Sharma at the University of Michigan bound niclosamide to a dendrimer by click chemistry, then added a folate group so only cells with the matching receptor take it up.
- Scans showed the drug homing on the affected endometrial tissue and not accumulating in other organs such as the liver.
- A single injection cut pain symptoms against untreated mice and slowed, and in some cases halted, the growth of new lesions.
Why it matters
- capability If it translated, one lesion-targeted injection would differ from hormonal treatment, which brings nausea and mood swings, and from surgery, after which lesions often regrow.
- constraint Mice do not naturally menstruate or develop endometriosis, so the lesion model mimics the disease without reproducing it, and the human work is still ahead.
- decision Trial endpoints have to be chosen. An outside researcher, Ioannis Simitsidellis, lists "chronic pelvic pain and infertility" as the main symptoms, and the mouse results described cover pain, inflammation and lesion growth.
Niclosamide is approved by the Food and Drug Administration for tapeworm infections [5], and the group had already seen it work on endometriosis in mice. "We have reported that niclosamide inhibits endometriosis progression, suppressing the inflammatory mechanisms and cytokine secretions," Hayashi said, referring to that earlier work [16]. The obstacle was practical. The compound dissolves poorly in water, does not last long in the body and does not go to the cells where it is needed [6].
Sharma, who built the carrier, described the intended behaviour. "The drug is attached in such a way that when it is in systemic circulation, nothing happens until it goes inside the diseased cells," she said [9]. Once inside, the drug is released slowly over two weeks [10].
The work was reported in August in the journal Advanced Healthcare Materials [1]. The comparison Live Science describes is with untreated mice [12]. That shows the treated animals did better than animals given nothing. It leaves open how much the carrier adds over free niclosamide, which the group's earlier work had already found helpful in mice [16]. Live Science did not report group sizes, how pain was scored, how far lesion growth fell, or how long the effect lasted after one injection. "Dramatically" is the outlet's word for the pain reduction [12], not a measured effect size.
The thing this doesn't tell you is whether the folate-receptor immune cells the carrier seeks are present in human lesions. They were identified in mouse tissue [8]. In our view the result is a credible demonstration of targeted delivery in a model that mimics the lesions, and we'd expect any clinical plan to begin by confirming that those cells exist in human tissue.
If the approach holds, the population is large: roughly 10% of reproductive-age females, an estimated 190 million individuals worldwide [4].
What to watch
- Whether the full paper or a follow-up reports head-to-head arms against free niclosamide and a carrier without drug.
- Whether folate-receptor immune cells like those found in mouse lesions are confirmed in human endometriosis tissue.
- A trial registration or regulatory filing from the team, with its dose, schedule and endpoints.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence40
- Adoption3
- Hype gap+15
- Incentives
- Insufficient
- Confidence45
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
Researchers reported in August, in the journal Advanced Healthcare Materials, that the modified niclosamide treatment reduced inflammation and slowed or prevented further spread of endometriosis lesions in mice.
- [2]
The team is already working on bringing the new drug to clinical trials and hopes this will bring fresh attention to an understudied disease with limited treatment options.
- [3]
Endometriosis is a chronic, hormone-driven condition in which tissue similar to the uterine lining grows outside the uterus; the lesions trigger painful inflammation and heavy menstrual bleeding.
- [4]
Endometriosis affects roughly 10% of reproductive-age females, an estimated 190 million individuals worldwide.
- [5]
Niclosamide is a drug approved by the US Food and Drug Administration to treat tapeworm infections.
- [6]
Niclosamide does not dissolve well in water, does not last long in the body, and does not target the cells where it is needed most.
- [7]
Anjali Sharma, a nanomedicine specialist at the University of Michigan, used click chemistry to attach the niclosamide unit to a tree-like dendrimer molecule, which helped it dissolve in blood, and then added a folate group so the drug would target only cells with the complementary receptor.
- [8]
In previous research with mice, Kanako Hayashi, a professor at the Washington State University School of Molecular Biosciences, identified a group of rogue immune cells specific to endometrial lesion tissue that turbocharged inflammatory reactions and drove lesion growth; the cells carry a folate receptor.
- [9]
"The drug is attached in such a way that when it is in systemic circulation, nothing happens until it goes inside the diseased cells," Sharma said.
- [10]
Once inside the cell, the drug is slowly released over a period of two weeks.
- [11]
Scans of the mice showed the treatment zeroed in on the affected endometrial tissue and did not accumulate in other organs, such as the liver.
- [12]
Live Science reported that treating mice with a single injection dramatically reduced their pain symptoms compared with untreated mice, and slowed or in some cases entirely halted the growth of new lesions.
- [13]
Because mice do not naturally menstruate or develop endometriosis, there is significant work to do before the findings can be replicated in humans.
- [14]
Hormonal medications can stall the menstrual cycle to limit lesion growth and inflammation but can bring side effects such as nausea and mood swings, and surgery can remove lesions but they often regrow.
- [15]
"The main symptoms are chronic pelvic pain and infertility," said Ioannis Simitsidellis, a postdoctoral researcher at the University of Edinburgh's Centres for Reproductive Health and Inflammation Research, who was not involved in the study.
- [16]
"We have reported that niclosamide inhibits endometriosis progression, suppressing the inflammatory mechanisms and cytokine secretions," Hayashi said, referring to the group's past work in mice.
Get this ledger inside ChatGPT. Ask about any of our stories and the answer brings its figure, each claim’s verdict and the sources. Free, no account.
Sources
1 independent publisher whose own reporting we read for this story.
- livescience.comTapeworm drug could help treat endometriosis, mouse study hints
1 article · October 14, 2026
Topics and entities
Follow any of these and your For You feed starts watching them — no settings page required.
Topics
Entities
- NiclosamideFollow
- Kanako HayashiFollow
- Anjali SharmaFollow
- Washington State UniversityFollow
- University of MichiganFollow
- Advanced Healthcare MaterialsFollow
- Live ScienceFollow